Peptide Initiative

Peptides · Peptide comparison

Fertirelin vs Triptorelin

A potent GnRH analog designed to support reproductive function in veterinary and research settings

GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeFertirelin50–100 mcgTriptorelin11.25–11.25 mg
FrequencyFertirelinOnce dailyTriptorelinOnce daily
AdministrationFertirelinIntramuscular injectionTriptorelinIntramuscular injection
Cycle lengthFertirelinOngoing/indefiniteTriptorelinOngoing/indefinite
Onset speedFertirelinModerate (1-2 weeks)TriptorelinModerate (1-2 weeks)
Evidence levelFertirelinModerate human trials (Phase 1-2)TriptorelinStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Reproductive Synchronization

Fertirelin82%
TriptorelinNo recorded rating

Hormone Support

Fertirelin78%
TriptorelinNo recorded rating

Veterinary Breeding Enhancement

Fertirelin74%
TriptorelinNo recorded rating

Hormone Regulation

FertirelinNo recorded rating
Triptorelin94%

Cancer Management

FertirelinNo recorded rating
Triptorelin90%

Endometriosis Relief

FertirelinNo recorded rating
Triptorelin87%

Technical data

Compound specifications

Fertirelin

Molecular formula
C55H76N16O12
Molecular weight
1153.3 g/mol
Half-life
Variable depending on formulation; sustained-release formulations extend duration
Bioavailability
High when administered via injection
CAS number
66002-66-2

Triptorelin

Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4

Protocols

Dosing compared

Fertirelin

Intramuscular

  • 50-100 mcg per animalSingle injection at the defined point in the synchronization protocol · Single dose (repeated per breeding cycle as needed)Fertirelin is a veterinary GnRH agonist. In dairy cattle, 50 mcg and 100 mcg intramuscular both triggered an LH surge and comparable conception rates for ovulation synchronization and fixed-time insemination [4]. Used to induce ovulation and improve conception in cattle [1].

Triptorelin

Intramuscular injection

  • 3.75 mgOnce every 4 weeks · Ongoing while indicatedFDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
  • 11.25 mgOnce every 12 weeks · Ongoing while indicatedFDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
  • 22.5 mgOnce every 24 weeks · Ongoing while indicatedFDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].

Applications

Best suited for

Fertirelin

Livestock breeding programs
Fertirelin is particularly well-suited for individuals focused on livestock breeding programs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reproductive synchronization in cattle
Fertirelin is particularly well-suited for individuals focused on reproductive synchronization in cattle. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Fertility enhancement in veterinary settings
Fertirelin is particularly well-suited for individuals focused on fertility enhancement in veterinary settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research on reproductive hormone mechanisms
Fertirelin is particularly well-suited for individuals focused on research on reproductive hormone mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Triptorelin

Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Fertirelin

Common

  • Mild discomfort at treatment site
  • Transient hormone fluctuations
  • Temporary behavioral changes in animals
  • Mild injection site reactions
  • Short-term changes in appetite
  • Temporary mood variations
  • Minimal systemic effects at therapeutic doses

Uncommon

  • Occasional swelling at injection site

Serious

  • Severe allergic reaction

Triptorelin

No side effects recorded.

Research status

Safety & evidence

Fertirelin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Fertirelin is a GnRH agonist developed specifically for veterinary use in livestock, particularly cattle breeding and fertility management. The peptide has been safely used in veterinary medicine for over 40 years with a well-documented safety profile in animals. Important limitation: Fertirelin is NOT approved for human use. All safety and efficacy data comes from veterinary applications in cattle and limited laboratory research. Human safety data is minimal and extrapolation from veterinary use is problematic. The biphasic response (initial hormone surge followed by suppression) must be carefully managed in any application. Individual responses can vary significantly based on age, hormonal status, and concurrent medications.

Contraindications

  • Pregnancy (may disrupt existing pregnancy)
  • Hypersensitivity to GnRH analogs
  • Active reproductive infections
  • Concurrent use with certain medications
  • Undiagnosed reproductive disorders

Triptorelin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Contraindications

  • Pregnancy (can affect fetal development)
  • Undiagnosed vaginal bleeding
  • Known hypersensitivity to GnRH agonists
  • Severe untreated depression
  • Active spinal cord compression in prostate cancer (requires urgent decompression)

Decision guide

Which is right for you?

Fertirelin

Choose Fertirelin if…

  • Livestock breeding programs
  • Reproductive synchronization in cattle
  • Fertility enhancement in veterinary settings
  • Research on reproductive hormone mechanisms

Triptorelin

Choose Triptorelin if…

  • Managing advanced prostate cancer when combined with other treatments
  • Relieving severe endometriosis pain and symptoms
  • Delaying puberty development in children with early sexual maturation